http://WWW.ADVANCEDRESPIRATORYCENTRE.COM
DRRANJITSINGH 58f4a983e229e60a187a8889 False 110 1
OK
background image not found
Found Update results for
'idiopathic pulmonary fibrosis'
5
2000 classification of idiopathic interstitial lung diseases The 2000 classification consists of seven entities of idiopathic interstitial diseases which are defined on clinical, radiological and pathological criteria: idiopathic pulmonary fibrosis, non-specific interstitial pneumonia, cryptogenic organizing pneumonia, acute interstitial pneumonia, respiratory bronchiolitis associated interstitial lung disease, desquamative interstitial pneumonia and lymphoid interstitial pneumonia. The most frequent is Idiopathic Pulmonary Fibrosis, which has a poor prognosis.
Bronchoscopic Lung Cryobiopsy Increases Diagnostic Confidence in the Multidisciplinary Diagnosis of Idiopathic Pulmonary Fibrosis American Journal of Respiratory and Critical Care Medicine Volume 193 Number 7 | April 1 2016 BLC is a new biopsy method that has a meaningful impact on diagnostic confidence in the multidisciplinary diagnosis of interstitial lung disease and may prove useful in the diagnosis of IPF.
Pirfenidone Reduces Respiratory-related Hospitalizations in Idiopathic Pulmonary Fibrosis In a pooled analysis of three phase 3 IPF clinical trials, patients receiving pirfenidone had a lower risk of non-elective respiratory-related hospitalization over 1 year. Among those hospitalized for any reason, pirfenidone was associated with a lower risk of death following hospital admission.
Personalised Medicine for Asthma and Chronic Obstructive Pulmonary Disease Asthma and chronic obstructive pulmonary disease (COPD) are prevalent condition sboth significant heterogeneity within each of these conditions and additionally significant overlap in many of the clinical and inflammatory features useful clinical and immunological biomarkers which inform about prognosis and response to therapy have emerged in both asthma and COPD. These biomarkers will allow both better targeting of existing treatments and the identification of those patients who will respond to novel therapies which are now becoming available Delivery of precision medicine in airways disease is now feasible and is a core component of a personalised healthcare delivery in asthma and COPD
Blood Eosinophils and Response to Maintenance Chronic Obstructive Pulmonary Disease Treatment. Data from the FLAME Trial. indacaterol/glycopyrronium provides superior or similar benefits over salmeterol/fluticasone regardless of blood eosinophil levels in patients with COPD The incidence of pneumonia was higher in patients receiving salmeterol/fluticasone than indacaterol/glycopyrronium in both the <2% and ≥2% subgroups Indacaterol/glycopyrronium was significantly superior to salmeterol/fluticasone for the prevention of exacerbations
1
false